Clinical Trial Update: Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of Turoctocog alfa pegol (N8-GP) in previously untreated patients with Haemophilia A; results have been posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Esperoct (turoctocog alfa pegol)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2024-10-31